FDA: Hospira recalls four lots of Labetalol Hydrochloride
Editor's Note
The Food and Drug Administration (FDA) on February 23 announced the recall by Hospira Inc (Lake Forest, Illinois) of three lots of Labetalol Hydrochloride Injection, USP, 100 mg/20 mL vial (NDC 0409-2267-25), and one lot of Labetalol Hydrochloride Injection, USP, Novaplus (NDC 0409-2267-25).
The recall was initiated because of the discovery of cracks on the rim surfaces of vials in these lots. Cracked vials may result in a lack of sterility assurance.
The lots were distributed nationwide from April 2017 to August 2017.
Posted 02/23/2018] AUDIENCE: Pharmacy, Risk Manager, Nursing ISSUE: Hospira is voluntarily recalling 3 lots of Labetalol Hydrochloride Injection, USP, 100 mg/20 mL Vial (NDC 0409-2267-20), and one lot of Labetalol Hydrochloride Injection, USP, Novaplus (NDC 0409-2267-25) to the hospital/institution level. Hospira, Inc.
Free Daily News
- Survey assesses continued impact of Change Healthcare cyberattack
- WHO sounds alarm on potential spread of bird flu
- Allison Massari to deliver hopeful, empowering keynote address at OR Manager Conference 2024
- Neurosurgery trial: Early evacuation improves long-term hemorrhage outcomes
- Drug shortages higher than ever
- FDA announces class 1 recalls for premixed embolic, infusion pump software
- Academic medical centers identify performance-improvement priorities
- Propofol anesthesia for colonoscopy could help find polyps, prevent cancer
- FDA Class 1 recall renews concern about historically problematic heart pumps
- New physician compensation report reveals modest pay gains but growing discontent with the profession